Fundraising FoxCarcinotech
Edinburgh, GB · 12 known investors
Find your way into Carcinotech
Sign up to find every way you can get introduced to Carcinotech
- Your email: who you already know at Carcinotech, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Carcinotech team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Carcinotech produces bioprinted tumor models combining patient-derived biological material with automated workflows to generate reproducible tumor tissue systems for drug discovery and testing. The platform serves pharmaceutical researchers and drug development teams evaluating therapeutic efficacy before in vivo studies.
Founders & leadership
Investors · 12
How we know: Alba Equity's portfolio page · uktech.news · Not right? Tell us
How we know: TRICAPITAL's portfolio page · uktech.news · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: uktech.news · Not right? Tell us
How we know: uktech.news · Not right? Tell us
How we know: funding news · businesscloud.co.uk · Not right? Tell us
How we know: uktech.news · Not right? Tell us
Also in the syndicate · 1
Companies House · registry record
View on Companies House ↗- Registered name
- CARCINOTECH LTD
- Company number
- SC604026
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 31 Jul 2018
- Registered office
- Roslin Innovation Centre, Easter Bush Campus, Edinburgh, Midlothian, EH25 9RG
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2024 · next due 30 Sept 2026
- Confirmation statement
- last made up to 30 Jul 2026 · next due 13 Aug 2027
Current officers · 4
- Mbm Secretarial Services Limited — corporate secretary, appointed 23 Jan 2023
- Lorna Ewart — director, appointed 4 Jun 2024
- Albert Nicholl — director, appointed 2 Oct 2020
- Ian David Waddell — director, appointed 3 May 2022
Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Carcinotech do?
- Carcinotech produces bioprinted tumor models combining patient-derived biological material with automated workflows to generate reproducible tumor tissue systems for drug discovery and testing. The platform serves pharmaceutical researchers and drug development teams evaluating therapeutic efficacy before in vivo studies.
- Who are Carcinotech's investors?
- Carcinotech's investors include Alba Equity, TRICAPITAL, British Business Bank, Eos Advisory, Gabriel Investment Syndicate, Investing Women Angels, Investment Fund for Scotland, Maven Capital and 3 more.
- Where is Carcinotech headquartered?
- Carcinotech is headquartered in Edinburgh, GB.